• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Follow-up: Prozac intrigue fizzles


In February ( http://www.contemporarypediatrics.com/contpeds/article/articleDetail.jsp?id=147795), Updates reported an accusation made by the British Medical Journal (BMJ) that pharmaceutical manufacturer Eli Lilly & Co. had concealed documents linking the company's antidepressant Prozac (fluoxetine) to a heightened risk of suicide. Updates noted that Lilly denied the allegation but, regrettably, the February issue of Contemporary Pediatrics had already gone to press when BMJ editors retracted their statement and apologized to Lilly: "The BMJ accepts that Eli Lilly acted properly in relation to the disclosure of these documents ... and is happy to set the record straight and apologize."

Related Videos
Deborah Persaud, MD
Ari Brown, MD, FAAP | Pediatrician and CEO of 411 Pediatrics; author, baby411 book series; chief medical advisor, Kabrita USA.
Steven Selbst, MD
© 2024 MJH Life Sciences

All rights reserved.